Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: No guarantees that Baroni evaluation is complete

SGE,

Eventually the revenue generated by the licencing of the MMP will run out. I believe PTSC always knew that the MMP would only take them so far and that mutual fund type investors would need to see a future beyond the MMP for them to invest in PTSC. Now it can be argued the way it has gone down so far that perhaps PTSC was premature in their aquisitions and they should have kept expenses down and invested the MMP money more safely, however, on the flip side the Crossflow part does seem to be timed right with the planned upgrades of secure data in the health care industry and first response government agencies including homeland secrurity. It seems that the BOD as bad as their performance appears to look so far, did recognized that PDSG wasn't heading in the right direction as quickly as they had planned and they had the forsight, perhaps influenced somwhat by disgruntled shareholders, to bring in outside expertise to provide some much needed guidance to make sure the company was headed in the right direction going forward.

IMO Brians "last chance" post may be exactly what the BOD may feel at this time. That is, I think they recognize that they have not delivered and the growing numbers of disgruntled investors are starting to put some pressure on them to show some results. In that respect I believe the BOD feels they are running out of time.

It should be interesting to see what takes place in January leading up to the shareholder meeting.

All the best,

Steve

Share
New Message
Please login to post a reply